PTTG1 and neoplasm: Given its role in corticotroph tumor pathogenesis, PTTG overexpression may be a potential target for Cushing’s disease treatment with HDACi (Trichostatin) or SD1029, an anti-fungal agent and a potent JAK-STAT pathway inhibitor that targets PTTG to suppress AtT20 cell proliferation [47].